ASH 2023: The Most Relevant Multiple Myeloma Data Presented
Joshua Richter, MD, led an enthusiastic panel with his colleagues in the multiple myeloma space following the 2023 ASH Annual Meeting and Exposition.
HER3-DXd May Lead to an Additional Treatment Option in EGFR+ NSCLC
Helena A. Yu, MD, and Sandip P. Patel, MD, reviewed the use of patritumab deruxtecan, which was assessed in the phase 2 HERTHENA-Lung01 trial.
Detailing the Impact on SOC in GI Cancer After ASCO GI
Jun Gong, MD, and Daneng Li, MD, discussed the most impactful trials coming from 2024 ASCO GI.
Inpatient vs Outpatient Use of Teclistamab in Multiple Myeloma
Experts in multiple myeloma debated the use of teclistamab through an inpatient or outpatient setting.
Experts Examine the Need for Targeted Therapy Options for KRAS G12C–Mutated NSCLC
Narjust Florez, MD, and Sandip P. Patel, MD, cohosted a X chat centering on treatment options for KRAS G12C non–small cell lung cancer.
Clinicians Face Off Regarding New Trials in NSCLC Space
The CROWN and ADURA trials were discussed and defended as part of a non–small cell lung cancer Face Off.
Multiple Myeloma and ALL Experts Face Off in Data Analyzing Cilta-Cel and Ponatinib Hydrochloride
Vanderbilt University Medical Center and Winship Cancer Institute at Emory University Face Off on recent data in multiple myeloma and acute lymphoblastic leukemia.
Reviewing the Approval Process of Teclistamab in Multiple Myeloma
A group of experts discussed the approval process for teclistamab use in patients with multiple myeloma.
Defining a Space for NRG1 Fusion–Positive Tumors in Lung and GI Cancers
An overview of NRG1 fusion–positive tumors was given by experts in the gastrointestinal and lung cancer space in a recent Frontline Forum.
Menin Inhibitors Show Promise in Future AML Treatment
Ghayas C. Issa, MD, gave an all-encompassing review of current treatment options for acute myeloid leukemia and what to expect in the future.
Patient's Perspective on Pembrolizumab/Lenvatinib Use in RCC
Thomas Hutson, DO, PharmD, meets with his patient Cesar Fuentes to discuss his diagnosis and treatment for renal cell carcinoma.
Targeted Therapy Options for HER2+ Breast Cancer
A Satellite Session, involving members from US Oncology, focused on treatment options for patients with HER2-positive metastatic breast cancer.
Immunotherapy/TKI Combinations Yield Efficacy Benefit in RCC
During a Morning Rounds discussion, experts in the field of renal cell carcinoma reviewed treatment updates and the effective use of immunotherapy plus TKIs.
A Variety of Treatment Options Are Becoming Available in CRC
Kristen K. Ciombor, MD, MSCI, gives an overview of the current treatment landscape for patients with metastatic colorectal cancer.
New Lung Cancer Treatment Options Combine Neoadjuvant and Adjuvant Therapies
Misako Nagasaka, MD, PhD, sheds light on neoadjuvant and adjuvant treatment options for patients with lung cancer.
Key Data Overview in NSCLC From ESMO 2023
During the European Society for Medical Oncology 2023, experts discussed updated results in key trials across the lung cancer space.
Mayo Clinic Reviews Outpatient Techniques for Monitoring Post CAR T-Cell Therapy
In a recent Training Academy, experts discussed how to incorporate bispecific antibodies into patients with multiple myeloma.
Treatment Recommendations for Relapsed Multiple Myeloma
Experts in the multiple myeloma space met to discuss the treatment and monitoring after bispecific antibodies.
BTK Inhibitor Treatment Strategies in Chronic Lymphocytic Leukemia
Asher A. Chanan-Khan, MBBS, MD, led a panel discussion surround the use of Bruton tyrosine kinase inhibitors for patients with chronic lymphocytic leukemia.
Treatment Updates and Key Highlights in Multiple Myeloma and CML
Karmanos Cancer Institute and Cleveland Clinic gave presentations regarding treatment of multiple myeloma and chronic myeloid leukemia in the latest Face Off.
Personalized Treatment Sequencing Is a New Way of Thinking in Breast Cancer
Sara M. Tolaney, MD, MPH, gives an extensive overview on the current breast cancer landscape and available treatment options.
Adverse Effect Management in Non–Small Cell Lung Cancer Treatment
Misako Nagasaka, MD, PhD, and Kristen Neumann, DNP, FNP-C, discussed how to best mitigate adverse effects in patients with non–small cell lung cancer.
Mayo Clinic and UT Southwestern “Face Off” Over Multiple Myeloma and CML
UT Southwestern and Mayo Clinic debated over current treatment options in chronic myeloid leukemia and multiple myeloma.
Fred Hutch and City of Hope “Face Off” on Ixazomib Vs Olverembatinib in CML and Multiple Myeloma
Fred Hutch and City of Hope "Face Off" regarding presentations focusing on multiple myeloma and chronic myeloid leukemia.
Future CRC Treatment to Focus on Mutation Status, Expert Says
Tanios S. Bekaii-Saab, MD, gave an overview of colorectal cancer along with current standard of care, and potential treatment options.
JAK Inhibitors, Mutations, and Transplantation in Myelofibrosis Management
John O. Mascarenhas, MD, led a panel discussion on myelofibrosis management including the use of JAK inhibitors and transplantation.
Don’t Be Afraid to Ask Questions Along the Bladder Cancer Journey, Patients and Clinicians Advise
A patient with bladder cancer recounts his diagnosis while Rohit Jain, MD, and Anand B. Shah, PharmD, BCOP, review treatment options and the toxicity associated with them.
Selecting and Sequencing Ruxolitinib, Other Treatments in Chronic GVHD
Nelson J. Chao, MD, MBA, and his colleagues discussed the use of ruxolitinib as treatment for patients with graft-vs-host disease.
Lenvatinib Plus Pembrolizumab Yields Continuous Efficacy in CLEAR Trial for Advanced RCC
Brian I. Rini, MD, led a panel where he and his colleagues discussed the results of the CLEAR trial and its implications in renal cell carcinoma.
ASCO 2023: Experts Recount the Biggest Surprises and Most Relevant Research
Experts met to debate recently presented trials in the hematologic oncology after the 2023 American Society of Clinical Oncology Annual Meeting.
